Temozolomide Therapy for Aggressive Pituitary Tumors: Results in a Small Series of Patients from ArgentinaReport as inadecuate




Temozolomide Therapy for Aggressive Pituitary Tumors: Results in a Small Series of Patients from Argentina - Download this document for free, or read online. Document in PDF available to download.

International Journal of Endocrinology - Volume 2015 2015, Article ID 587893, 8 pages -

Clinical Study

Foundation of Endocrinology, 1425 Buenos Aires, Argentina

Pathology Laboratory, Hospital Italiano, 1199 Buenos Aires, Argentina

Division of Endocrinology, Hospital de Clínicas, University of Buenos Aires, 1120 Buenos Aires, Argentina

Received 23 February 2015; Revised 6 May 2015; Accepted 6 May 2015

Academic Editor: Andre P. Kengne

Copyright © 2015 Oscar D. Bruno et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

We evaluated results of temozolomide TMZ therapy in six patients, aged 34–78 years, presenting aggressive pituitary tumors. In all the patients tested O

-methylguanine-DNA methyltransferase MGMT immunoexpression in surgical specimens was absent. Patients received temozolomide 140–320 mg-day for 5 days monthly for at least 3 months. In two patients minimum time for evaluation could not be reached because of death in a 76-year-old man with a malignant prolactinoma and of severe neutro-thrombopenia in a 47-year-old woman with nonfunctioning pituitary adenoma. In two patients a 34-year-old acromegalic woman and a 39-year-old woman with Nelson’s syndrome no response was observed after 4 and 6 months, respectively, and the treatment was stopped. Conversely, two 52- and 42-year-old women with Cushing’s disease had long-term total clinical and radiological remissions which persisted after stopping temozolomide. We conclude that TMZ therapy may be of variable efficacy depending on—until now—incompletely understood factors. Cooperative work on a greater number of cases of aggressive pituitary tumors should be crucial to establish the indications, doses, and duration of temozolomide administration.





Author: Oscar D. Bruno, Lea Juárez-Allen, Silvia B. Christiansen, Marcos Manavela, Karina Danilowicz, Carlos Vigovich, and Reynaldo

Source: https://www.hindawi.com/



DOWNLOAD PDF




Related documents